Translational stroke research | 2021

The Genetic Basis of Moyamoya Disease.

 
 
 
 
 
 
 
 

Abstract


Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a puff of smoke (Japanese: Moyamoya) on cerebral angiography. These\xa0pathological alterations of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to limit the stenotic lesions or the development of a\xa0collateral network is available, the only treatment established so far is surgical revascularization. The pathophysiology still remains unknown. Due to the early\xa0age of onset, familial cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be replicated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells, cytokines and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a ubiquitously expressed 591\xa0kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed as a susceptibility gene in several studies with a\xa0gene dosage-dependent clinical phenotype, allowing preventive screening and possibly\xa0the\xa0 development of new therapeutic approaches. This review focuses on the genetic basis of primary MMD only.

Volume None
Pages None
DOI 10.1007/s12975-021-00940-2
Language English
Journal Translational stroke research

Full Text